Budget Amount *help |
¥17,160,000 (Direct Cost: ¥13,200,000、Indirect Cost: ¥3,960,000)
Fiscal Year 2021: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2020: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2019: ¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2018: ¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
|
Outline of Final Research Achievements |
The route of administration of oncolytic herpes simplex virus (HSV) in the majority of clinical trials to date has been direct injection into the tumor. This appears to be one of the factors that may limit the therapeutic potential of oncolytic HSV as a single agent against systemically metastatic tumors. To overcome this limitation, we have developed a receptor-retargeted oncolytic herpes simplex virus employing a single-chain antibody for targeting tumor-associated antigens (RR-oHSV) and its modified version with additional mutations conferring syncytia formation (RRsyn-oHSV). Here, we investigated the in vivo anti-tumor effects of RRsyn-oHSV using human cancer xenografts in immunodeficient mice. Intra-venous administration of RRsyn-oHSV resulted in robust anti-tumor effects even against large tumors. These results strongly suggest that cancer patients with distant metastases could be effectively treated with our RRsyn-oHSV.
|